Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3095761 | 0.84 | NPC1 (0.70) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL13895390 | 0.81 | MEN1 (0.57) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL3190680 | 0.81 | MEP1B (0.53) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL13368580 | 0.78 | NPC1 (0.49) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL968919 | 0.78 | NPC1 (0.67) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL9547511 | 0.77 | NPC1 (0.66) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL5188163 | 0.75 | NPC1 (0.63) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL27577931 | 0.75 | NPC1 (0.68) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL8426730 | 0.75 | PRSS1 (0.56) | NPC1RAB9AKMT2ATDP1ALDH1A1 | |
| SCHEMBL2565715 | 0.75 | F2 (0.51) | KMT2ATDP1MEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279576-B2 | Anti-cancer medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1590344-A4 | ANTI-CANCER MEDICAMENTS | DECIPHERA PHARMACEUTICALS LLC (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1590344-A2 | ANTI-CANCER MEDICAMENTS | Deciphera Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040176395-A1 | Anti-cancer medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2004-09-09 | — | — | US | disclosed |
| WO-2004060305-A2 | ANTI-CANCER MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176395-A1 | Anti-cancer medicaments | ABL1, ABL2, SRC | NPC1 4548/4885RAB9A 2813/4885CA12 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.